Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06445075 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
A Phase 2 study, sponsored by Scholar Rock.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT06445075 is a Phase 2 study that has completed, run by Scholar Rock. The registered enrollment target is 102 participants.
The verdict
NCT06445075, a Phase 2 study, has completed, sponsored by Scholar Rock.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity
Interventions
- DRUG Placebo
- DRUG Tirzepatide
- DRUG Apitegromab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2024-05-21 |
| Est. Completion | 2025-06-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06445075
The ClinicalTrials.gov registry entry for NCT06445075 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scholar Rock, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06445075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06445075 about?
NCT06445075 is a clinical study titled "Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese". A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity
What is the current status of trial NCT06445075?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2024-05-21. Estimated completion is 2025-06-17.
What interventions are being tested in trial NCT06445075?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG), Apitegromab (DRUG).
Who is sponsoring clinical trial NCT06445075?
This trial is sponsored by Scholar Rock, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.